 FibroGen, Inc. NASDAQ: FGEN shares are trading lower after an FDA Advisory Committee panel voted against approval of the companys New Drug Application for roxadustat to treat anemia due to chronic kidney disease in adult patients. While we are disappointed with todays outcome, said CEO Enrique Conterno, we believe the scientific evidence supports roxadustat approval in the U.S. and will work with the FDA as it completes its review of the New Drug Application for roxadustat. 